<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355832</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00090432</org_study_id>
    <nct_id>NCT04355832</nct_id>
  </id_info>
  <brief_title>Glucagon-like Peptide-1 in Type 1 Diabetes</brief_title>
  <official_title>Reducing Hypoglycemic, Pro-coagulant and Pro-atherothrombotic Responses and Preventing Hypoglycemia Associated Autonomic Failure in Type 1 DM. The Effects of Glucagon-like Peptide-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypotheses to be tested in this application is: GLP-1 will acutely protect arterial&#xD;
      endothelial function and reduce pro-atherothrombotic and pro-coagulant effects of repeated&#xD;
      hypoglycemia in T1DM.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The naturally occurring hormone GLP-1 when co-administered during hypoglycemia (low blood&#xD;
      sugar) in non-diabetic individuals can reduce the deleterious effects of hypoglycemia on the&#xD;
      vasculature. We have shown that IV infusion of GLP-1 during a single moderate episode of&#xD;
      hypoglycemia can preserve endothelial function and protect the vasculature from pro-coagulant&#xD;
      and pro-inflammatory effects in healthy individuals.&#xD;
&#xD;
      It is unknown whether GLP-1 could protect the vasculature during episodes of repeated&#xD;
      hypoglycemia and whether GLP-1 would have protective effects in T1DM individuals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the level of catecholamines in plasma</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The participants will be randomized to placebo infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The participants will be randomized to placebo infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will be randomized to Glucagon-like peptide-1 infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon-like peptide-1</intervention_name>
    <description>Infusion of Glucagon-like peptide-1</description>
    <arm_group_label>GLP-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Infusion of normal saline solution that will mimic Glucagon-like peptide-1</description>
    <arm_group_label>Placebo 1</arm_group_label>
    <arm_group_label>Placebo 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  40 (20 males, 20 females) individuals with type 1 diabetes aged 18-50 yr.&#xD;
&#xD;
          -  HbA1c &lt; 11.0%&#xD;
&#xD;
          -  Body mass index &lt; 40kg • m-2&#xD;
&#xD;
          -  No clinically diagnosed diabetic tissue complications (i.e. history of retinopathy,&#xD;
             neuropathy, stasis ulcers, etc)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects unable to give voluntary informed consent&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Subjects on anticoagulant drugs, anemic or with known bleeding diatheses&#xD;
&#xD;
          -  Subjects taking any of the following medications will be excluded: non-selective beta&#xD;
             blockers,&#xD;
&#xD;
          -  sedative-hypnotics, anticonvulsants, antiparkinsonian drugs, antipsychotics,&#xD;
             antidepressants,&#xD;
&#xD;
          -  mood stabilizers, CNS stimulants, opioids, hallucinogens&#xD;
&#xD;
          -  Subjects unwillingness or inability to comply with approved contraception measures&#xD;
&#xD;
          -  Subjects with a history of severe uncontrolled hypertension (i.e., blood pressure&#xD;
             greater than 160/100), heart disease, cerebrovascular incidents&#xD;
&#xD;
          -  Clinically significant cardiac abnormalities (e.g. heart failure, arrhythmias,&#xD;
             ischemic tachycardia, S-T segment deviations, etc.) from history or from cardiac&#xD;
             stress testing in subjects ≥ 40 years old.&#xD;
&#xD;
          -  Pneumonia&#xD;
&#xD;
          -  Hepatic failure /jaundice&#xD;
&#xD;
          -  Abnormal results following screening tests and physical examination that are&#xD;
             clinically significant&#xD;
&#xD;
          -  Acute cerebrovascular/ neurological deficit&#xD;
&#xD;
          -  Fever greater than 38.0 C&#xD;
&#xD;
          -  Screening Laboratory Tests Exclusion Criteria&#xD;
&#xD;
          -  Hematocrit lower than 32&#xD;
&#xD;
          -  WBC lower than 3 thou/ul or greater than 14 thou/ul&#xD;
&#xD;
          -  Liver function tests: SGOT and SGPT greater than twice upper limit of normal range&#xD;
             (i.e. &gt; 80 U/L)&#xD;
&#xD;
          -  TBil &gt; 2 mg/dl&#xD;
&#xD;
          -  Creatinine &gt; 1.6 mg/dl&#xD;
&#xD;
          -  Alkaline phosphatase &gt; 150U/L&#xD;
&#xD;
          -  Hepatic transaminase &gt; 2x normal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maka S Hedrington, MD</last_name>
    <phone>410-706-5623</phone>
    <email>mhedrington@som.umaryland.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephen N Davis, MBBS</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maka Hedrington, MD</last_name>
      <phone>615-715-9494</phone>
      <email>mhedrington@som.umaryland.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Stephen N. Davis, MBBS</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

